百奥泰BAT5906临床试验获批准

Core Viewpoint - Company Baiotai (688177) has received approval from the National Medical Products Administration for its investigational drug BAT5906, which targets retinal central vein occlusion-related macular edema (CRVO-ME) and pathological myopia-related choroidal neovascularization (pmCNV) [1] Group 1 - BAT5906 is a recombinant humanized monoclonal antibody innovative drug developed and produced by the company [1] - The drug is an IgG1 type full-length antibody with a molecular weight of 149KDa [1] - BAT5906 specifically binds to human VEGF-A165, inhibiting neovascularization [1]